参考文献/References:
[1] Ren L,Huang S,Beck J,et al.Impact of limb amputation and cisplatin chemotherapy on metastatic progression in mouse models of osteosarcoma[J].Sci Rep,2021,11(1):24435.
[2] Shen Y,Zhao S,Wang S,et al.S1P/S1PR3 axis promotes aerobic glycolysis by YAP/c-MYC/PGAM1 axis in osteosarcoma[J].Ebio Medicine,2019,40:210-223.
[3] 陈 伟,刘海生,魏 萌,等.熊果酸对荷骨肉瘤大鼠免疫功能的影响[J].环球中医药,2017,10(3):279-283.
[4] 徐建立,孙艳华,李 明,等.紫草素通过抑制上皮间质转化缓解结肠癌细胞5-氟尿嘧啶耐药[J].陕西中医,2022,43(3):296-300.
[5] 王 莹,牟琪瑞,刘春英,等.补中益气汤联合顺铂对肺腺癌荷瘤裸鼠移植瘤连环蛋白mRNA及蛋白表达的影响[J].中华中医药杂志,2022,37(4):2191-2194.
[6] 孟庆龙,刘雅婧,崔文玉,等.刺五加多糖抗炎作用的研究[J].时珍国医国药,2019,30(11):2621-2624.
[7] Sun D,Chen J,Hu H,et al.Acanthopanax senticosus polysaccharide suppressing proliferation and metastasis of the human non-small cell lung cancer NCI-H520 cells is associated with Wnt/β-catenin signaling[J].Neoplasma,2019,66(4):555-563.
[8] 杨 健,张立喜,史 博.石见穿多糖通过PTEN通路对骨肉瘤小鼠的抑瘤作用及对免疫功能的影响[J].天津中医药,2022,39(7):940-944.
[9] 张 娜,赵良友,毛 迪,等.刺五加多糖调控炎性因子对小鼠免疫性肝损伤的保护作用[J].中国中药杂志,2019,44(14):2947-2952.
[10] 李 森,王 健,古钦文,等.寄生软化汤诱导骨肉瘤小鼠的免疫效应[J].世界中医药,2018,13(6):1518-1520,1524.
[11] Wu NF,Yamamoto J,Bouvet M,et al.A novel procedure for orthotopic tibia implantation for establishment of a more clinical osteosarcoma PDOX mouse model[J].In Vivo,2021,35(1):105-109.
[12] Corre I,Verrecchia F,Crenn V,et al.The osteosarcoma microenvironment:A complex but targetable ecosystem[J].Cells,2020,9(4):976.
[13] 刘怀毫,梁 振,梁沛杰,等.骨肉瘤化学治疗的研究进展[J].中国临床新医学,2018,11(3):311-314.
[14] Meng Q,Pan J,Liu Y,et al.Anti-tumour effects of polysaccharide extracted from acanthopanax senticosus and cell-mediated immunity[J].Exp Ther Med,2018,15(2):1694-1701.
[15] 陈靖昀,于书剑,肖 冬.刺五加多糖对肿瘤干细胞的作用研究[J].中国实验诊断学,2019,23(7):1233-1238.
[16] 辛欢欢,李春玲,王贵平.白花蛇舌草黄酮注射液对小鼠脾淋巴细胞的免疫增强作用[J].中国兽医科学,2010,40(7):752-757.
[17] 杜娜雯,白日兰,崔久嵬.肿瘤免疫逃逸机制及治疗策略[J].中国肿瘤生物治疗杂志,2019,26(4):454-462.
[18] 陈 玉,肖海娟,王惠玲,等.基于伏邪理论探讨恶性肿瘤发病机制[J].陕西中医,2022,43(12):1760-1762,1767.
[19] 郭家毓,呼 群.小细胞肺癌免疫治疗研究进展[J].陕西医学杂志,2023,52(1):118-121.
[20] Jiang W,Pan S,Chen X,et al.The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy[J].Mol Cancer,2021,20(1):116.
[21] Huang X,Zhang W,Zhang Z,et al.Prognostic value of programmed cell death 1 ligand-1(PD-L1)or PD-1 expression in patients with osteosarcoma:A meta-analysis[J].J Cancer,2018,9(14):2525-2531.
[22] 梁乐乐,王 鹏,刘俊霞,等.非小细胞肺癌组织中T细胞免疫球蛋白区黏蛋白-3、程序性死亡因子-1及程序性因子配体1的表达分析[J].陕西医学杂志,2021,50(10):1227-1230.
[23] Shimizu T,Fuchimoto Y,Okita H,et al.A curative treatment strategy using tumor debulking surgery combined with immune checkpoint inhibitors for advanced pediatric solid tumors:An in vivo study using a murine model of osteosarcoma[J].J Pediatr Surg,2018,53(12):2460-2464.
[24] Shimizu T,Fuchimoto Y,Fukuda K,et al.The effect of immune checkpoint inhibitors on lung metastases of osteosarcoma[J].J Pediatr Surg,2017,52(12):2047-2050.
[25] Zheng B,Ren T,Huang Y,et al.PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse[J].J Hematol Oncol,2018,11(1):16.